Kalaris Therapeutics, Inc.
4.8700-0.13 (-2.6%)
Oct 29, 4:00:02 PM EDT · NasdaqGM · KLRS · USD
Key Stats
Market Cap
91.08MP/E (TTM)
-Basic EPS (TTM)
-2.71Dividend Yield
0%Recent Filings
8-K
Annual meeting elects directors
Kalaris Therapeutics held its 2025 Annual Meeting on August 12, electing Srinivas Akkaraju, M.D., Ph.D., and Andrew Oxtoby as Class II directors for three-year terms ending in 2028, with strong support of over 14.6 million votes each amid minimal withholding. Stockholders also ratified Deloitte & Touche LLP as independent auditors for the fiscal year through December 31, 2025, passing decisively with 16.1 million for votes. Governance stays steady.
8-K
Kalaris Q2 loss widens on trial ramp-up
Kalaris Therapeutics reported Q2 2025 net loss of $11.4 million, up from $5.7 million year-over-year, driven by $8.4 million in R&D expenses as the Phase 1 trial for TH103 in nAMD patients advances. Cash reserves hit $88.4 million post-merger with AlloVir, funding operations into Q4 2026. Initial safety and efficacy data expected Q4 2025. Clinical delays pose risks.
10-Q
Q2 FY2025 results
Kalaris Therapeutics posted a $11.4M net loss for Q2 FY2025 ended June 30, 2025, up from $5.7M a year earlier, driven by $12.3M in operating expenses that swelled 193% y/y amid ramped-up R&D for its lead anti-VEGF candidate TH103. R&D costs jumped 163% y/y to $8.4M, fueled by Phase 1 trial initiation and manufacturing scale-up, while G&A expenses more than tripled to $3.8M on merger-related professional fees and public company costs. The Merger with AlloVir closed in March 2025 for stock consideration, injecting $102.1M in cash and recognizing no goodwill or intangibles beyond existing assets. Cash and equivalents stood at $88.4M at quarter-end, with no debt outstanding and free cash flow not disclosed in the 10-Q. Yet regulatory hurdles loom large for TH103's path to approval.
8-K
2025 annual meeting scheduled
10-Q
Q1 2025 results
Kalaris Therapeutics, Inc. reported a net loss of $10.2 million for Q1 2025, with R&D expenses at $6.0 million and G&A at $4.3 million. The company raised $102.1 million in cash through the merger with AlloVir, ending with $101.0 million in cash reserves. Key developments include the completion of the merger on March 18, 2025, and the initiation of a Phase 1 trial for TH103 in nAMD, with first patient dosed in August 2024. No revenue was generated, and the company remains pre-revenue with a focus on retinal disease treatments.
ACRS
Aclaris Therapeutics, Inc.
2.34-0.05
IMA
ImageneBio, Inc.
8.79+0.09
KALA
KALA BIO, Inc.
0.80-0.03
KLTO
Klotho Neurosciences, Inc.
0.52-0.01
KPRX
Kiora Pharmaceuticals, Inc.
2.53+0.08
LENZ
LENZ Therapeutics, Inc.
30.64-0.17
NBY
NovaBay Pharmaceuticals, Inc.
1.20-0.06
OCS
Oculis Holding AG
21.55+0.55
OTLK
Outlook Therapeutics, Inc.
1.28-0.05
TRML
Tourmaline Bio, Inc.
47.98+47.98